Literature DB >> 3091234

In-vitro susceptibility of 400 isolates of Neisseria gonorrhoeae in Vancouver, 1982-84.

W R Bowie, C E Shaw, D G Chan, H D Jones, W A Black.   

Abstract

Consecutive isolates of Neisseria gonorrhoeae obtained at a sexually transmitted disease clinic in Vancouver between June 1982 and June 1984 were tested for in-vitro susceptibility to eight antimicrobial agents. Of the 400 isolates 6 (1.5%) were penicillinase-producing N. gonorrhoeae, and for 25 (6.2%) the minimum inhibitory concentrations (MICs) of penicillin were 1.0 to 4.0 micrograms/ml. Ceftriaxone sodium was the most active agent. The MICs were higher than those reported in a Canadian study in 1973-74, except for tetracycline hydrochloride. The patterns of susceptibility of the isolates to one antimicrobial agent correlated significantly with those to each other agent, although the relation was weakest for trimethoprim-sulfamethoxazole and spectinomycin. The results reinforce the need to evaluate local in-vitro susceptibility patterns, especially since the proportion of isolates with relative and absolute resistance to penicillin is increasing.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091234      PMCID: PMC1491522     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  11 in total

1.  Modification of the rapid fermentation test for Neisseria gonorrhoeae.

Authors:  W J Brown
Journal:  Appl Microbiol       Date:  1974-06

2.  Rapid penicillinase paper strip test for detection of beta-lactamase-producing Haemophilus influenzae and Neisseria gonorrhoeae.

Authors:  J H Jorgensen; J C Lee; G A Alexander
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

3.  Epidemiology and therapy of Chlamydia trachomatis infections.

Authors:  W R Bowie
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

4.  Ceftriaxone in the treatment of ordinary and penicillinase-producing strains of Neisseria gonorrhoeae.

Authors:  V S Rajan; E H Sng; T Thirumoorthy; C L Goh
Journal:  Br J Vener Dis       Date:  1982-10

5.  Cross-Canada survey of susceptibility of Neisseria gonorrhoeae isolates to six antimicrobial agents.

Authors:  J R Dillon; L Eidus; B B Diena
Journal:  Can Med Assoc J       Date:  1978-08-12       Impact factor: 8.262

6.  Penicillinase-producing Neisseria gonorrhoeae: results of surveillance in the United States.

Authors:  M S Siegel; C Thornsberry; J W Biddle; P R O'Mara; P L Perine; P J Wiesner
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

7.  Neisseria gonorrhoeae strains isolated in Hong Kong: in vitro susceptibility to 13 antibiotics.

Authors:  W S Ng; P Anton; K Arnold
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

8.  NEISSERIA GONORRHOEAE. I. VIRULENCE GENETICALLY LINKED TO CLONAL VARIATION.

Authors:  D S KELLOGG; W L PEACOCK; W E DEACON; L BROWN; D I PIRKLE
Journal:  J Bacteriol       Date:  1963-06       Impact factor: 3.490

9.  Transferable resistance and aminoglycoside-modifying enzymes in enterococci.

Authors:  H Y Chen; J D Williams
Journal:  J Med Microbiol       Date:  1985-10       Impact factor: 2.472

10.  Comparison of ceftriaxone with cefoxitin in the treatment of penicillin-resistant gonococcal urethritis.

Authors:  T R Zajdowicz; P L Sanches; S W Berg; S B Kerbs; R L Newquist; W O Harrison
Journal:  Br J Vener Dis       Date:  1983-06
View more
  3 in total

1.  Need for treatment of gonorrhea to be effective against Chlamydia trachomatis.

Authors:  W R Bowie; J Ast; L Sibau; C Shaw; H D Jones; W A Black
Journal:  Can J Infect Dis       Date:  1993-11

2.  Urethral discharge in the male.

Authors:  W R Bowie
Journal:  Can Fam Physician       Date:  1987-08       Impact factor: 3.275

3.  In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis.

Authors:  W R Bowie; C E Shaw; D G Chan; W A Black
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.